Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 75 | 2022 | 13380 | 1.530 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 42 | 2018 | 5315 | 1.260 |
Why?
|
Movement | 12 | 2016 | 1478 | 1.130 |
Why?
|
Fluorodeoxyglucose F18 | 11 | 2018 | 2010 | 0.970 |
Why?
|
Carcinoma, Small Cell | 16 | 2003 | 420 | 0.910 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 14 | 2018 | 1661 | 0.910 |
Why?
|
Esophageal Neoplasms | 16 | 2016 | 1654 | 0.900 |
Why?
|
Respiration | 8 | 2013 | 1657 | 0.750 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2014 | 423 | 0.680 |
Why?
|
Radiation Pneumonitis | 5 | 2018 | 102 | 0.630 |
Why?
|
Radiotherapy Dosage | 22 | 2017 | 2898 | 0.570 |
Why?
|
Radiopharmaceuticals | 5 | 2014 | 2651 | 0.550 |
Why?
|
Positron-Emission Tomography | 8 | 2018 | 6485 | 0.490 |
Why?
|
Neoadjuvant Therapy | 11 | 2016 | 2827 | 0.460 |
Why?
|
Radiotherapy, Conformal | 5 | 2014 | 548 | 0.440 |
Why?
|
Tomography, X-Ray Computed | 16 | 2022 | 20570 | 0.380 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 146 | 0.370 |
Why?
|
Thymus Neoplasms | 7 | 2013 | 274 | 0.360 |
Why?
|
Combined Modality Therapy | 42 | 2011 | 8529 | 0.350 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2018 | 9280 | 0.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 24 | 2016 | 11742 | 0.330 |
Why?
|
Radiation Injuries | 7 | 2018 | 1189 | 0.330 |
Why?
|
Thymoma | 6 | 2013 | 188 | 0.320 |
Why?
|
Radiotherapy | 10 | 2018 | 1499 | 0.280 |
Why?
|
Cisplatin | 19 | 2016 | 1651 | 0.260 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2018 | 801 | 0.240 |
Why?
|
Neoplasm Staging | 23 | 2018 | 11121 | 0.230 |
Why?
|
Glucose | 6 | 2014 | 4346 | 0.230 |
Why?
|
Amifostine | 1 | 2003 | 40 | 0.230 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 88 | 0.220 |
Why?
|
DNA Repair | 1 | 2011 | 2045 | 0.200 |
Why?
|
Lung | 8 | 2018 | 10000 | 0.200 |
Why?
|
Respiratory Mechanics | 1 | 2006 | 699 | 0.200 |
Why?
|
Paclitaxel | 5 | 2018 | 1732 | 0.190 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1222 | 0.190 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2898 | 0.180 |
Why?
|
Aged | 59 | 2022 | 169289 | 0.180 |
Why?
|
Adenocarcinoma | 12 | 2011 | 6346 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 12 | 2011 | 4026 | 0.160 |
Why?
|
Aged, 80 and over | 26 | 2018 | 58976 | 0.160 |
Why?
|
Carcinoma, Bronchogenic | 3 | 1986 | 87 | 0.160 |
Why?
|
Imaging, Three-Dimensional | 3 | 2008 | 4063 | 0.150 |
Why?
|
Nuclear Proteins | 2 | 2011 | 5796 | 0.150 |
Why?
|
Tomography, Emission-Computed | 7 | 2004 | 1122 | 0.140 |
Why?
|
Middle Aged | 60 | 2018 | 220895 | 0.140 |
Why?
|
Carboplatin | 3 | 2018 | 794 | 0.130 |
Why?
|
Fluorouracil | 11 | 2006 | 1641 | 0.130 |
Why?
|
Lymph Nodes | 1 | 2007 | 3466 | 0.130 |
Why?
|
Survival Rate | 14 | 2017 | 12725 | 0.130 |
Why?
|
Radiosurgery | 2 | 2018 | 1342 | 0.130 |
Why?
|
Male | 64 | 2018 | 360804 | 0.130 |
Why?
|
Humans | 99 | 2022 | 761504 | 0.120 |
Why?
|
Tumor Burden | 5 | 2016 | 1893 | 0.120 |
Why?
|
Thymectomy | 2 | 2013 | 195 | 0.120 |
Why?
|
Female | 66 | 2018 | 392644 | 0.120 |
Why?
|
Probability | 3 | 2013 | 2477 | 0.120 |
Why?
|
Sensitivity and Specificity | 6 | 2014 | 14666 | 0.120 |
Why?
|
Spinal Cord Neoplasms | 2 | 1987 | 263 | 0.120 |
Why?
|
Pneumonectomy | 4 | 2009 | 1119 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 321 | 0.120 |
Why?
|
Lung Injury | 1 | 2018 | 422 | 0.110 |
Why?
|
Respiratory Function Tests | 4 | 1994 | 1682 | 0.100 |
Why?
|
Esophagitis | 3 | 2003 | 164 | 0.090 |
Why?
|
Analysis of Variance | 2 | 2011 | 6228 | 0.090 |
Why?
|
Lung Diseases | 2 | 1994 | 1909 | 0.090 |
Why?
|
Lymphatic Metastasis | 4 | 2010 | 2915 | 0.090 |
Why?
|
Etoposide | 5 | 2013 | 634 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 276 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2022 | 2056 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2016 | 4853 | 0.090 |
Why?
|
Deoxyglucose | 3 | 1996 | 333 | 0.090 |
Why?
|
Protein Array Analysis | 1 | 2011 | 400 | 0.090 |
Why?
|
Adult | 37 | 2018 | 221177 | 0.080 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2011 | 426 | 0.080 |
Why?
|
ras Proteins | 1 | 2014 | 1054 | 0.080 |
Why?
|
Lymphatic Irradiation | 1 | 2009 | 115 | 0.080 |
Why?
|
Preoperative Care | 4 | 2013 | 2242 | 0.080 |
Why?
|
Feasibility Studies | 6 | 2018 | 5247 | 0.070 |
Why?
|
Carcinoma | 3 | 2013 | 2330 | 0.070 |
Why?
|
Carcinoma, Large Cell | 2 | 2007 | 113 | 0.070 |
Why?
|
Prospective Studies | 10 | 2017 | 54425 | 0.070 |
Why?
|
Fluorine Radioisotopes | 3 | 1996 | 418 | 0.070 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 202 | 0.070 |
Why?
|
Brain Neoplasms | 5 | 2014 | 9031 | 0.070 |
Why?
|
Artifacts | 2 | 2008 | 1911 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1626 | 0.070 |
Why?
|
Mediastinum | 1 | 2007 | 267 | 0.070 |
Why?
|
Treatment Outcome | 17 | 2014 | 64680 | 0.070 |
Why?
|
Consensus | 1 | 2016 | 3123 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2016 | 6814 | 0.070 |
Why?
|
Point Mutation | 1 | 2011 | 1595 | 0.060 |
Why?
|
Radiometry | 2 | 2018 | 813 | 0.060 |
Why?
|
Monte Carlo Method | 2 | 2013 | 1258 | 0.060 |
Why?
|
Retrospective Studies | 16 | 2018 | 80636 | 0.060 |
Why?
|
Scattering, Radiation | 2 | 2018 | 490 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2008 | 3514 | 0.060 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2002 | 882 | 0.060 |
Why?
|
Neoplasm Invasiveness | 3 | 2013 | 3595 | 0.060 |
Why?
|
Pericardial Effusion | 1 | 1987 | 247 | 0.060 |
Why?
|
Dura Mater | 1 | 1987 | 290 | 0.060 |
Why?
|
Risk | 5 | 2018 | 9610 | 0.060 |
Why?
|
Esophagogastric Junction | 3 | 2016 | 347 | 0.060 |
Why?
|
Prognosis | 10 | 2011 | 29625 | 0.060 |
Why?
|
Radiotherapy, High-Energy | 2 | 1981 | 228 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2008 | 1784 | 0.060 |
Why?
|
Neoplasm Proteins | 2 | 2011 | 3617 | 0.050 |
Why?
|
Regression Analysis | 1 | 2013 | 6343 | 0.050 |
Why?
|
Troponin T | 1 | 2008 | 780 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2014 | 6484 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4511 | 0.050 |
Why?
|
Reference Values | 1 | 2009 | 4920 | 0.050 |
Why?
|
Smoking | 1 | 2018 | 9053 | 0.050 |
Why?
|
Treatment Failure | 3 | 2003 | 2645 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2872 | 0.050 |
Why?
|
Organs at Risk | 2 | 2016 | 359 | 0.050 |
Why?
|
Camptothecin | 2 | 2016 | 591 | 0.050 |
Why?
|
Genotype | 2 | 2014 | 12990 | 0.050 |
Why?
|
Radiation Dosage | 3 | 2018 | 1958 | 0.050 |
Why?
|
Follow-Up Studies | 10 | 2017 | 39106 | 0.050 |
Why?
|
Lymphatic System | 1 | 2002 | 254 | 0.040 |
Why?
|
Fibrosarcoma | 1 | 2002 | 309 | 0.040 |
Why?
|
Bayes Theorem | 2 | 2018 | 2330 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2018 | 20098 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 1723 | 0.040 |
Why?
|
Clinical Trials as Topic | 5 | 2016 | 8002 | 0.040 |
Why?
|
Melanoma, Experimental | 1 | 2002 | 560 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2001 | 15266 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2003 | 1334 | 0.040 |
Why?
|
Meningeal Neoplasms | 1 | 1987 | 1248 | 0.040 |
Why?
|
Cranial Fossa, Posterior | 2 | 1987 | 135 | 0.030 |
Why?
|
Survival Analysis | 6 | 2008 | 10090 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 9000 | 0.030 |
Why?
|
Anorexia | 1 | 2016 | 154 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2008 | 5112 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1996 | 283 | 0.030 |
Why?
|
Photons | 1 | 2018 | 589 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2011 | 7856 | 0.030 |
Why?
|
Time Factors | 9 | 2013 | 39967 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9606 | 0.030 |
Why?
|
Ventilation-Perfusion Ratio | 1 | 1994 | 117 | 0.030 |
Why?
|
Postoperative Period | 3 | 1991 | 1813 | 0.030 |
Why?
|
Nausea | 1 | 2016 | 679 | 0.030 |
Why?
|
Protons | 1 | 2018 | 1116 | 0.030 |
Why?
|
Antineoplastic Agents | 5 | 2003 | 13639 | 0.030 |
Why?
|
Computer Simulation | 1 | 2006 | 6240 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 1999 | 1432 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2005 | 3357 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15936 | 0.020 |
Why?
|
Vinblastine | 3 | 2002 | 488 | 0.020 |
Why?
|
Radiography | 3 | 2009 | 6965 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2013 | 312 | 0.020 |
Why?
|
Pleural Neoplasms | 1 | 1996 | 609 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2011 | 10209 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2011 | 8547 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2016 | 625 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 12463 | 0.020 |
Why?
|
North America | 1 | 2013 | 1276 | 0.020 |
Why?
|
Lymphoma | 1 | 1979 | 1901 | 0.020 |
Why?
|
Mesothelioma | 1 | 1996 | 807 | 0.020 |
Why?
|
Remission Induction | 2 | 2008 | 2396 | 0.020 |
Why?
|
Safety | 1 | 1994 | 1150 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2005 | 4320 | 0.020 |
Why?
|
Forced Expiratory Volume | 1 | 1994 | 1814 | 0.020 |
Why?
|
Blood Gas Analysis | 1 | 1990 | 379 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2691 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 590 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4021 | 0.020 |
Why?
|
Young Adult | 4 | 2018 | 59243 | 0.020 |
Why?
|
Linear Models | 1 | 2018 | 5871 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12059 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3201 | 0.020 |
Why?
|
Esophagus | 2 | 2010 | 1033 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1987 | 372 | 0.020 |
Why?
|
Exhalation | 1 | 2007 | 181 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 611 | 0.020 |
Why?
|
Mediastinal Diseases | 1 | 2007 | 91 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1745 | 0.020 |
Why?
|
Risk Factors | 5 | 2018 | 74206 | 0.020 |
Why?
|
Algorithms | 2 | 2005 | 14031 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 787 | 0.020 |
Why?
|
Brain Ischemia | 1 | 1999 | 3049 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2850 | 0.020 |
Why?
|
Medicare | 1 | 2022 | 6770 | 0.010 |
Why?
|
Water | 1 | 2009 | 1411 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3579 | 0.010 |
Why?
|
Pilot Projects | 2 | 2013 | 8631 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 2013 | 1459 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2927 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2002 | 127 | 0.010 |
Why?
|
Lymphography | 1 | 2002 | 188 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1980 | 15 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 1999 | 36426 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 2002 | 915 | 0.010 |
Why?
|
Immunoenzyme Techniques | 2 | 1996 | 1705 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26125 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 883 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 12974 | 0.010 |
Why?
|
Cough | 1 | 2004 | 594 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2005 | 876 | 0.010 |
Why?
|
Extracellular Space | 1 | 2002 | 563 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 21353 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2011 | 2811 | 0.010 |
Why?
|
Taxoids | 1 | 2003 | 668 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2002 | 673 | 0.010 |
Why?
|
Postoperative Care | 1 | 1986 | 1468 | 0.010 |
Why?
|
Technetium Tc 99m Exametazime | 1 | 1999 | 61 | 0.010 |
Why?
|
Peptides | 1 | 1991 | 4358 | 0.010 |
Why?
|
Vesicular Transport Proteins | 1 | 2002 | 376 | 0.010 |
Why?
|
Cerebral Arterial Diseases | 1 | 1999 | 82 | 0.010 |
Why?
|
Pressure | 1 | 2002 | 1154 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 384 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2002 | 2016 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2002 | 1606 | 0.010 |
Why?
|
Blood Volume | 1 | 1999 | 547 | 0.010 |
Why?
|
Odds Ratio | 1 | 2009 | 9646 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1988 | 4915 | 0.010 |
Why?
|
Microscopy | 1 | 2002 | 903 | 0.010 |
Why?
|
Mutation | 2 | 2011 | 30052 | 0.010 |
Why?
|
Membrane Transport Proteins | 1 | 2002 | 1035 | 0.010 |
Why?
|
Animals | 3 | 2003 | 168459 | 0.010 |
Why?
|
Mice, Nude | 1 | 2002 | 3615 | 0.010 |
Why?
|
Sarcoma | 1 | 1987 | 1801 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2009 | 5294 | 0.010 |
Why?
|
Biopsy | 1 | 2007 | 6766 | 0.010 |
Why?
|
Arterial Occlusive Diseases | 1 | 1999 | 748 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 1987 | 2538 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6132 | 0.010 |
Why?
|
Glycoproteins | 1 | 2002 | 2203 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1068 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 1999 | 983 | 0.010 |
Why?
|
United States | 1 | 2022 | 72334 | 0.010 |
Why?
|
Ki-67 Antigen | 1 | 1996 | 629 | 0.010 |
Why?
|
Patient Care Planning | 1 | 1999 | 908 | 0.010 |
Why?
|
Breast Neoplasms | 2 | 1993 | 21012 | 0.010 |
Why?
|
Neoplasms | 1 | 2002 | 22170 | 0.010 |
Why?
|
Blood Vessels | 1 | 1998 | 1113 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1999 | 1474 | 0.010 |
Why?
|
Gastrin-Releasing Peptide | 1 | 1991 | 37 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1979 | 1374 | 0.010 |
Why?
|
Cranial Irradiation | 1 | 1994 | 390 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1979 | 1181 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15631 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1992 | 641 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2003 | 10766 | 0.010 |
Why?
|
Forecasting | 1 | 2000 | 2928 | 0.010 |
Why?
|
Blood Glucose | 2 | 1996 | 6391 | 0.010 |
Why?
|
Carcinoid Tumor | 1 | 1991 | 224 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1999 | 2727 | 0.000 |
Why?
|
RNA, Neoplasm | 1 | 1991 | 750 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 2002 | 11076 | 0.000 |
Why?
|
Image Enhancement | 1 | 1999 | 2885 | 0.000 |
Why?
|
Acute Disease | 1 | 1999 | 7237 | 0.000 |
Why?
|
Cohort Studies | 1 | 2011 | 41487 | 0.000 |
Why?
|
Infusions, Intravenous | 1 | 1993 | 2219 | 0.000 |
Why?
|
In Situ Hybridization | 1 | 1991 | 1900 | 0.000 |
Why?
|
Cell Cycle | 1 | 1996 | 2932 | 0.000 |
Why?
|
Doxorubicin | 1 | 1994 | 2224 | 0.000 |
Why?
|
Risk Assessment | 1 | 2008 | 23995 | 0.000 |
Why?
|
Contrast Media | 1 | 1999 | 5311 | 0.000 |
Why?
|
Particle Accelerators | 1 | 1986 | 174 | 0.000 |
Why?
|
Thorax | 1 | 1987 | 555 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1987 | 2218 | 0.000 |
Why?
|
Quality of Life | 1 | 1982 | 13367 | 0.000 |
Why?
|
Gene Expression | 1 | 1991 | 7581 | 0.000 |
Why?
|
Hydrocortisone | 1 | 1986 | 1819 | 0.000 |
Why?
|
Models, Biological | 1 | 1994 | 9469 | 0.000 |
Why?
|
RNA, Messenger | 1 | 1991 | 12795 | 0.000 |
Why?
|
Mice | 1 | 2002 | 81525 | 0.000 |
Why?
|
Adolescent | 1 | 1994 | 88319 | 0.000 |
Why?
|
Brain | 1 | 1987 | 27112 | 0.000 |
Why?
|